Advertisement
Advertisement
U.S. Markets open in 8 hrs 18 mins
Advertisement
Advertisement
Advertisement
Advertisement

Galera Therapeutics, Inc. (GRTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.6700-0.1000 (-5.65%)
At close: 04:00PM EDT
Advertisement
Full screen
Loading interactive chart...
  • American City Business Journals

    Galera shares surge on news it will seek OK for lead drug candidate by year's end

    The experimental therapy is designed to treat a side effect of radiation therapy in cancer patients.

  • GlobeNewswire

    Galera Reports First Quarter 2022 Financial Results and Recent Corporate Updates

    Company plans to submit a New Drug Application (NDA) for avasopasem for the treatment of radiotherapy-induced severe oral mucositis (SOM) by end of 2022 Data from its Phase 3 ROMAN trial of avasopasem for SOM will be presented in an oral presentation at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Reported positive topline results from its Phase 2a AESOP trial of avasopasem for chemoradiotherapy-induced esophagitis MALVERN, Pa., May 16, 2022 (GLOBE NEWSWIRE) -- G

  • GlobeNewswire

    Galera Announces Plan to Submit Avasopasem NDA by Year End

    After discussions with FDA, Company is on track to file an NDA for avasopasem for the treatment of radiotherapy-induced severe oral mucositis by end of 2022MALVERN, Pa., May 16, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced its intent to file a New Drug Application (NDA)

Advertisement
Advertisement